OmniScreen™

Pre-Screening

Traditional molecular testing can be costly, time-consuming, and require a lot of tissue. Paige OmniScreen*™ offers a next-generation AI-driven approach to pre-screening for clinically relevant biomarkers, providing a faster, more cost-effective, and tissue-sparing alternative to traditional molecular testing. By bridging the gap between pathology and genomics, OmniScreen enables study participant selection, more efficient testing strategies, and streamlined decision-making across clinical and research settings.

A Smarter Approach to Molecular Testing

Accelerate Biomarker Discovery & Research

  • Paige OmniScreen replicates a targeted biomarker gene panel of 505 genes and can predict 1,600+ biomarkers in minutes.

  • Links phenotypic and genomic patterns, helping to identify new therapeutic targets and optimize biomarker-driven discovery.

 

Expedite Patient Enrollment

  • Quickly pre-screen patients for genomic-related eligibility criteria, limit molecular testing to only those meeting inclusion criteria, reducing recruitment timelines and costs.

  • Identify high-value cohorts based on AI-driven biomarker insights.

 

Reduce Costs & Conserve Tissue

  • Reduce molecular testing costs by narrowing down the pool of potential participants to those meeting the genomic-related inclusion criteria.  

  • Preserve finite tissue resources, sending only pre-screened potential participants to confirmatory NGS testing.

Why use Paige?

Scalable, and Ready for Integration

AI-Powered Confidence: Enables scalable biomarker analysis without the need for large datasets or additional tissue samples.

Optimized for Diverse Applications:

Supports oncology research, drug development, and clinical trial pre-screening. Enhances biomarker-driven discovery, early-phase research, and commercialization strategies.

Trial Design & Evidence Generation

Advancing precision medicine requires efficient patient selection, cost-effective molecular profiling, and seamless clinical trial integration.

Paige OmniScreen™ can be integrated into clinical trials as a:

Pre-screening tool to enhance patient selection

Predictive assay for identifying responders vs. non-responders

On-label companion diagnostic (CDx) to support regulatory approval pathways

Real-World Application: Pre-screening tool to enhance patient selection

Paige was the first in the industry to successfully deploy a digital AI biomarker into a clinical trial setting at 90 global sites in collaboration with a leading pharmaceutical partner. Validated as an AI pre-screening mechanism to streamline clinical trial efficiency, they achieved:

Rapid insights: Investigators received results within 1 hour, enabling informed molecular testing decisions

A centralized workflow: Digitized whole slide images were transmitted from three CROs, with AI results shared with investigators at individual clinical sites

Regulatory compliance: Adhered to ISO 13485 standards and classified as Software as a Medical Device (SaMD) under an IDE regulatory designation

Hassle-free integration: whole slide images were uploaded daily to the Paige platform and the AI was ran automatically​

Schedule a meeting today

And discover how AI-driven pre-screening can optimize your research and clinical workflows